Atovaquone‐proguanil showed no clear difference in total failure day 42 PCR‐adjusted compared with artesunate‐mefloquine (high certainty).
Atovaquone‐proguanil showed no clear difference in total failure day 42 PCR‐unadjusted compared with artesunate‐mefloquine (low certainty).
Atovaquone‐proguanil showed no clear difference in total failure day 28 PCR‐adjusted compared with artesunate‐atovaquone‐proguanil (low certainty).
Hydroxychloroquine (HCQ) showed no clear difference in negative PCR for SARS‐CoV‐2 on respiratory samples at day 14 from… compared with standard care or placebo (low certainty).
It is very uncertain whether hydroxychloroquine (HCQ) changes development of confirmed COVID‐19 at 14 days from enrolment compared with placebo (very low certainty).
The intervention showed no clear difference in treatment failure day‐28 PCR‐adjusted(PP population) (low certainty).
The intervention showed no clear difference in treatment failureday‐28 PCR‐adjusted(ITT population) (low certainty).
It is very uncertain whether the intervention changes clinical failure 1 to 14 days after end of treatment (very low certainty).
The intervention may leads to lower parasitological failure 1 to 14 days after end of treatment Method:… (low certainty).
Rapid antiretroviral therapy (ART) may leads to higher uptake of ART at 90 days compared with standard care (low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Macrolides showed no clear difference in resolution of fever within 5 days compared with doxycycline (low certainty).
Single dose primaquine at 0.2 to 0.25 mg/kg may leads to lower participants infectious at day 3‐4 compared with no primaquine, with artemisinin partner, (low certainty).
Single dose primaquine at 0.75 mg/kg showed no clear difference in participants infectious at day 3‐4 compared with no primaquine, with artemisinin partner, (low certainty).
Single dose primaquine at 0.75 mg/kg showed no clear difference in participants with gametocytes at day 3‐4, by PCR compared with no primaquine, with artemisinin partner, (low certainty).
Single dose primaquine at 0.75 mg/kg leads to lower participants with gametocytes at day 8, by PCR compared with no primaquine, with artemisinin partner, (high certainty).
Single dose primaquine at 0.4 to 0.5 mg/kg showed no clear difference in participants with gametocytes at day 4‐5, by microscopy compared with no primaquine, with non‐artemisinin partner, (moderate certainty).
Single dose primaquine at 0.4 to 0.5 mg/kg probably leads to lower participants with gametocytes at day 8, by microscopy compared with no primaquine, with non‐artemisinin partner, (moderate certainty).